BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell Clinical Trial

Official title:

A Phase I, Open, Dose Escalation Trial With BI 836826 in Patients With Advanced Chronic Lymphocytic Leukaemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01296932
• Other study ID #: 1270.1
• Secondary ID: 2010-021488-34
• Status: Completed
• Phase: Phase 1
• Start date: February 11, 2011
• Est. completion date: July 10, 2017

Study information

• Verified date: August 2020
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Adult patients with chronic lymphocytic leukaemia who experience a relapse after at least two prior treatment regimens may be enrolled in this trial. The trial will examine whether monotherapy with BI 836826 is safe and tolerable at escalating dose levels.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: July 10, 2017
• Est. primary completion date: May 30, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

1. Diagnosis of relapsed or refractory chronic lymphocytic leukaemia.

2. At least two prior treatment regimens for chronic lymphocytic leukaemia.

3. At least one criterion for active disease as defined by the International Workshop on CLL.

4. Absolute lymphocyte count lower than 200 x 10^9/l .

5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2.

6. Age 18 years or older.

7. Written informed consent which is consistent with International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) guidelines and local legislation.

Exclusion criteria:

1. Treatment with anti Cluster of Differentiation (CD) 20 therapy within 4 weeks, or alemtuzumab within 8 weeks, or any cytotoxic antileukemia therapy within 2 weeks, Ibrutinib or Idelalisib within 1 week prior to the first administration of the trial drug.

2. Prior allogeneic stem cell transplantation.

3. Active autoimmune haemolytic anemia.

4. Active autoimmune thrombocytopenia.

5. Known transformation to an aggressive B-cell malignancy.

6. Concurrent treatment with relevant doses of systemic glucocorticosteroids.

7. Prior history of malignancy other than chronic lymphocytic leukaemia (exceptions to this rule are defined in the clinical trial protocol).

8. Aspartate aminotransferase or alanine aminotransferase > 2.5 x upper limit of normal.

9. Total bilirubin > 1.5 x upper limit of normal.

10. Absolute Neutrophil Count < 1.000/µl.

11. Platelets < 25.000/µL.

12. Estimated Glomerular Filtration Rate <45 mL/min.

13. Proteinuria Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher.

14. Significant concurrent disease.

15. Any infectious disease requiring treatment at the time of enrolment or within the previous 2 weeks.

16. Hepatitis B or C.

17. Human Immunodeficiency Virus (HIV) infection.

18. Cytomegalovirus (CMV) viremia.

19. Women of childbearing potential not using a highly effective method of birth control during the trial until one year after the last dose.

20. Pregnancy or breast feeding.

21. Known or suspected active alcohol or drug abuse.

22. Treatment with another investigational drug within the past four weeks before start of therapy or concomitantly with this trial.

23. Prior treatment with BI 836826.

24. Patients unable to comply with the protocol

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid

Intervention

Drug:
• BI 836826
Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion.

Locations

Country	Name	City	State
Belgium	Brussels - UNIV Saint-Luc	Bruxelles
Belgium	Edegem - UNIV UZ Antwerpen	Edegem
Belgium	UNIV UZ Gent	Gent
France	INS Paoli-Calmettes	Marseille
France	CTR Investigation Clinique, onco, Montpellier	Montpellier Cedex 5
France	INS Universitaire du Cancer	Toulouse
Germany	Universitätsklinikum Frankfurt	Frankfurt am Main
Germany	Universitätsklinikum Heidelberg	Heidelberg
Germany	Universitätsklinikum Köln (AöR)	Köln
Germany	Universitätsklinikum Ulm	Ulm

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

Belgium,  France,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Patients With Dose-Limiting Toxicities Adverse Events (DLTs)	Dose-Limiting Toxicities (DLTs) were defined as any drug-related non-haematologic adverse event of Common Terminology Criteria for AE (CTCAE) Grade 3 or higher, except infusion related reactions associated with the administration of BI 836826. In addition complications due to haematologic AEs were considered as DLTs and were added in more detail in an amendment later on.	14 days after first administration of BI836826 (MTD evaluation period)
Primary	Maximum Tolerated Dose (MTD)	The maximum tolerated dose (MTD) was defined as the highest dose of BI 836826 studied for which the incidence of DLT was no more than 17% (i.e. 1 out of 6 patients) during the first treatment cycle. For those patients who received more than 1 cycle of BI 836826, all AEs corresponding to the DLT were considered for the purpose of confirming the MTD and for the selection of the recommended dose for treatment of the expansion cohort and for further development. All DLTs, occurring during the first or repeated treatment cycle were reported as significant AEs. As it was not possible to recruit a sufficient number of patients whilst the first part of the trial was still in progress, the recruitment was ended by the sponsor before the MTD or optimal biological dose (OBD) was reached.	14 days after first administration of BI836826 (MTD evaluation period)
Secondary	Best Percentage Change From Baseline in Number of Lymphocytes in the Peripheral Blood	In most patients with relapsed or refractory chronic lymphocytic leukaemia (CLL), malignant B-cells represent the majority of lymphocytes in the peripheral blood. Reduction of CLL-cells was assessed in the peripheral blood by absolute lymphocyte count, and flow cytometry. The number of lymphocytes in the peripheral blood was analysed in terms of the best percentage change from baseline until start of subsequent CLL therapy or progressive disease (PD).	baseline and =8 day after a completed infusion of a cycle and before Chronic Lymphocytic Leukemia (CLL) therapy; data collected up to cut-off date 26Oct2016, Up to 1809 days
Secondary	Number of Patients With Improved Haemoglobin Count for at Least Two Subsequent Response Assessments	In patients with haemoglobin counts below the limits of normal at baseline, improvement in this count during therapy potentially indicated a benefit for the patient. Number of patients with improved haemoglobin count for at least two subsequent response assessments which fulfil International Workshop on Chronic Lymphocytic Leukemia (IWCLL) response criteria for Complete Remission (CR) or Partial Remission (PR). The response was assessed before Progressive Disease (PD) or start of new Chronic Lymphocytic Leukaemia (CLL) therapy.	=8 day after a completed infusion of a cycle and before Chronic Lymphocytic Leukemia (CLL) therapy; data collected up to cut-off date 26Oct2016, Up to 1809 days
Secondary	Number of Patients With Improved Platelet Count for at Least Two Subsequent Response Assessments	In patients with platelet counts below the limits of normal at baseline, improvement in this count during therapy potentially indicated a benefit for the patient. Number of patients with improved platelet count for at least two subsequent response assessments which fulfil International Workshop on Chronic Lymphocytic Leukemia (IWCLL) response criteria for Complete Remission (CR) or Partial Remission (PR). The response was assessed before Progressive Disease (PD) or start of new Chronic Lymphocytic Leukaemia (CLL) therapy.	=8 day after a completed infusion of a cycle and before Chronic Lymphocytic Leukemia (CLL) therapy; data collected up to cut-off date 26Oct2016, Up to 1809 days
Secondary	Number of Patients With Improved Neutrophil Count for at Least Two Subsequent Response Assessments	In patients with neutrophil count below the limits of normal at baseline, improvement in this count during therapy potentially indicated a benefit for the patient. Number of patients with improved neutrophil count for at least two subsequent response assessments which fulfil International Workshop on Chronic Lymphocytic Leukemia (IWCLL) response criteria for Complete Remission (CR) or Partial Remission (PR). The response was assessed before Progressive Disease (PD) or start of new Chronic Lymphocytic Leukaemia (CLL) therapy.	=8 day after a completed infusion of a cycle and before Chronic Lymphocytic Leukemia (CLL) therapy; data collected up to cut-off date 26Oct2016, Up to 1809 days
Secondary	Best Overall Response According to 'International Workshop on Chronic Lymphocytic Leukemia' (IWCLL) Criteria	Response was assessed according to the IWCLL (International Workshop on Chronic Lymphocytic Leukemia) guidelines based on laboratory data from the peripheral blood and clinical examination by the investigator after each cycle prior to administration of the next dose of BI 836826, at the end of the treatment (EOT) visit, and at all Follow-up Visits. Best overall response will be analysed descriptively. Frequency distributions will be used to examine this endpoint.	Data collected up to cut-off date 26Oct2016 until Progressive disease (PD) to start of next Chronic Lymphocytic Leukaemia (CLL) therapy, Up to 1809 days.
Secondary	Progression-free Survival	Progression-free survival (PFS) was defined as the time from the first administration of BI 836826 until disease progression or death, whichever occurred first. Disease progression= At least one of the following: 50+% increase in blood lymphocytes over baseline with an absolute number of B-lymphocytes of at least 5x109/L; Progression of lymphadenopathy; 50+% increase in the previously noted enlargement of the liver or new appearance of hepatomegaly; 50+% increase in the previously noted enlargement of the spleen or new appearance of splenomegaly; 50+% Decrease of platelet counts or to less than 100x109/L secondary to CLL and unrelated to autoimmune cytopenia; Decrease of haemoglobin levels by more than 20 g/L, or to less than 100 g/L secondary to CLL and unrelated to autoimmune cytopenia T Transformation to a more aggressive histology, e.g. Richter syndrome.	Data collected up to cut-off date 26Oct2016, Up to 1809 days.
Secondary	Failure-free Survival	Failure-free survival (FFS) was defined as the time from the first administration of BI 836826 until disease progression or death, or start of next Chronic Lymphocytic Leukemia (CLL) therapy, whichever occurred first. Disease progression= At least one of the following: 50+% increase in blood lymphocytes over baseline with an absolute number of B-lymphocytes of at least 5x109/L; Progression of lymphadenopathy; 50+% increase in the previously noted enlargement of the liver or new appearance of hepatomegaly; 50+% increase in the previously noted enlargement of the spleen or new appearance of splenomegaly; 50+% Decrease of platelet counts or to less than 100x109/L secondary to CLL and unrelated to autoimmune cytopenia; Decrease of haemoglobin levels by more than 20 g/L, or to less than 100 g/L secondary to CLL and unrelated to autoimmune cytopenia T Transformation to a more aggressive histology, e.g. Richter syndrome.	Data collected up to cut-off date 26Oct2016, Up to 1809 days.

External Links

•   Related Info